Literature DB >> 28481430

Decreased frequency of circulating Th9 cells in patients with chronic hepatitis B infection.

Meilan Cui1, Ying Lv2, Jianhua Lu1, Wei Zhang1, Yuanyuan Duan2, Yan Huang1, Lei Yang3, Man Li3, Wenxuan Liu3, Dianwu Liu3, Huimin Yan1,2.   

Abstract

BACKGROUND: Chronic hepatitis B (CHB) is one of the major infectious diseases in which CD4+ T helper (Th) cells play a crucial role. Th9 cells are a distinct subset of CD4+ Th cells with important physiological functions.
OBJECTIVE: The study aimed to assess the potential involvement of Th9 cells in the inadequate immune response leading to chronic HBV infection. PATIENTS AND METHODS: Peripheral blood samples were collected from 22 CHB patients and 16 healthy controls (HC). The frequencies of circulating Th9, Tc9, Th1, and Tc1 cells were determined by flow cytometry. Serum levels of IL-9 and IL-10 were analyzed by ELISA. Serum biochemical indices of liver function were measured using an automated analyzers. Serum HBV DNA loads were analyzed by real-time PCR. The potential association of the frequency of Th9, Tc9, Th1 or Tc1 cells with clinical parameters was assessed.
RESULTS: The frequency of circulating Th9 cells was significantly lower in CHB patients than those in HC. However, no significant differences in the frequency of Tc9, Th1 or Tc1 cells were observed between the two groups. The percentages of Th9 cells, but not Tc9 cells, were negatively correlated with HBV DNA loads, whereas the percentages of Tc1 cells were positively correlated with viral loads in CHB patients. Moreover, there was a positive correlation between serum levels of IL-9 and IL-10 and HBV DNA loads in patients with chronic HBV infection.
CONCLUSION: The depletion of Th9 cells is associated with the development of chronic HBV infection.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Th1 cell; Th9 cell; chronic hepatitis B; immune response

Mesh:

Substances:

Year:  2017        PMID: 28481430      PMCID: PMC6817209          DOI: 10.1002/jcla.22246

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  35 in total

1.  [The guideline of prevention and treatment for chronic hepatitis B (2010 version)].

Authors: 
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2011-01

2.  Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis.

Authors:  Francesco Ciccia; Giuliana Guggino; Aroldo Rizzo; Antonio Manzo; Barbara Vitolo; Marco Pio La Manna; Giuseppina Giardina; Guido Sireci; Francesco Dieli; Carlo Maurizio Montecucco; Riccardo Alessandro; Giovanni Triolo
Journal:  Rheumatology (Oxford)       Date:  2015-07-15       Impact factor: 7.580

Review 3.  Host-virus interactions in hepatitis B virus infection.

Authors:  Luca G Guidotti; Masanori Isogawa; Francis V Chisari
Journal:  Curr Opin Immunol       Date:  2015-07-15       Impact factor: 7.486

4.  Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes.

Authors:  Anneli Jäger; Valérie Dardalhon; Raymond A Sobel; Estelle Bettelli; Vijay K Kuchroo
Journal:  J Immunol       Date:  2009-11-04       Impact factor: 5.422

Review 5.  Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases.

Authors:  Hai-Feng Pan; Rui-Xue Leng; Xiang-Pei Li; Song Guo Zheng; Dong-Qing Ye
Journal:  Cytokine Growth Factor Rev       Date:  2013-12       Impact factor: 7.638

6.  Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset.

Authors:  Marc Veldhoen; Catherine Uyttenhove; Jacques van Snick; Helena Helmby; Astrid Westendorf; Jan Buer; Bruno Martin; Christoph Wilhelm; Brigitta Stockinger
Journal:  Nat Immunol       Date:  2008-10-19       Impact factor: 25.606

7.  Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters.

Authors:  Chao Feng; Li-Juan Cao; Hua-Feng Song; Ping Xu; Hui Chen; Jun-Chi Xu; Xiao-Yan Zhu; Xue-Guang Zhang; Xue-Feng Wang
Journal:  Viral Immunol       Date:  2015-08-12       Impact factor: 2.257

8.  Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis.

Authors:  Jing Li; Shuang-Jian Qiu; Wei-Min She; Fu-Ping Wang; Hong Gao; Lei Li; Chuan-Tao Tu; Ji-Yao Wang; Xi-Zhong Shen; Wei Jiang
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

9.  IL-9 regulates allergen-specific Th1 responses in allergic contact dermatitis.

Authors:  Juan Liu; Erin Harberts; Antonella Tammaro; Nicholas Girardi; Renata B Filler; Rita Fishelevich; Angela Temann; Paula Licona-Limón; Michael Girardi; Richard A Flavell; Anthony A Gaspari
Journal:  J Invest Dermatol       Date:  2014-01-31       Impact factor: 8.551

10.  Serum Interleukin (IL)-9 and IL-10, but not T-Helper 9 (Th9) Cells, are Associated With Survival of Patients With Acute-on-Chronic Hepatitis B Liver Failure.

Authors:  Xueping Yu; Yijuan Zheng; Yong Deng; Julan Li; Ruyi Guo; Milong Su; Desong Ming; Zhenzhong Lin; Jiming Zhang; Zhijun Su
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

View more
  3 in total

1.  Irradiated whole-cell vaccine suppresses hepatocellular carcinoma growth in mice via Th9 cells.

Authors:  Junying Chen; Yuxiong Ding; Fei Huang; Ruilong Lan; Zeng Wang; Weikang Huang; Ruiqing Chen; Bing Wu; Lengxi Fu; Yunhua Yang; Jun Liu; Jinsheng Hong; Weijian Zhang; Lurong Zhang
Journal:  Oncol Lett       Date:  2021-03-22       Impact factor: 2.967

2.  Role of T-Helper 9 Cells in Chronic Hepatitis C-Infected Patients.

Authors:  Mohamed E Ali; Omnia El-Badawy; Noha A Afifi; Abeer Sharaf Eldin; Elham Ahmed Hassan; Hamada M Halby; Mohamed Ahmed El-Mokhtar
Journal:  Viruses       Date:  2018-06-24       Impact factor: 5.048

3.  Interleukin-35 Suppresses Interleukin-9-Secreting CD4+ T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma.

Authors:  Qian Zhang; Lanlan Yang; Siqi Liu; Mengyao Zhang; Zhenjing Jin
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.